论文部分内容阅读
目的:对子宫肌瘤患者行不同剂量的米非司酮治疗,观察临床疗效。方法:择取2015年11月~2016年5月期间收治的子宫肌瘤患者102例,通过平行对照法,将患者划分为实验组与参照组,每组各51例。对参照组患者行米非司酮常规剂量治疗,对实验组患者行小剂量米非司酮治疗,对比两组患者的临床治疗效果。结果:两组患者治疗前的子宫肌瘤体积、子宫体积无明显变化(P>0.05),治疗后,实验组患者的相关指标明显优于参照组患者,即组间差异P<0.05,具有统计学意义;实验组患者的临床治疗有效率为94.12%,明显高于参照组患者的80.39%,即数据对比,P<0.05,存在统计学差异。结论:对子宫肌瘤患者行小剂量米司非酮治疗,可以快速缓解患者的临床症状,优化临床治疗效果,具有临床普及使用的价值。
Objective: To treat patients with hysteromyoma with different dosages of mifepristone and observe the clinical curative effect. Methods: A total of 102 patients with uterine fibroids were selected from November 2015 to May 2016. The patients were divided into experimental group and reference group by the parallel control method, with 51 cases in each group. The reference group of patients with conventional dose of mifepristone treatment, the experimental group of patients with low-dose mifepristone treatment, the clinical efficacy of two groups were compared. Results: The volume of uterine fibroids and uterine volume before treatment in both groups had no significant changes (P> 0.05). After treatment, the relevant indicators in the experimental group were significantly better than those in the reference group, that is, the difference between groups was statistically significant (P <0.05) The clinical effective rate of the experimental group was 94.12%, which was significantly higher than 80.39% of the reference group, that is, the data comparison, P <0.05, there was a statistically significant difference. Conclusion: The low-dose mifepristone treatment for patients with uterine fibroids can quickly relieve the clinical symptoms of patients and optimize the clinical treatment, with the value of clinical popularization.